Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints

Contemporary Clinical Trials

Volumn 36, Issue 2, 2013, Pages 642-650

  Gu, Xuemin ^a   Yin, Guosheng ^b   Lee, J Jack ^c  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adaptive Lasso; Clinical trials; Group Lasso; Proportional hazards model; Targeted therapy design; Variable selection

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BAYES THEOREM; BAYESIAN TWO STEP LASSO STRATEGY; CLINICAL TRIAL (TOPIC); PERFORMANCE; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SIMULATION;

ADAPTIVE LASSO; CLINICAL TRIALS; GROUP LASSO; PROPORTIONAL HAZARDS MODEL; TARGETED THERAPY DESIGN; VARIABLE SELECTION;

BAYES THEOREM; BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MODELS, STATISTICAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84888134117     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.09.009     Document Type: Article

References (17)

1. Clayton D. A Monte Carlo method for Bayesian inference in frailty models. Biometrics 1991, 47:467-485.
2. Chipman H. Bayesian variable selection with related predictors. Can J Stat 1996, 24:17-36.
3. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc Ser B 1972, 34:187-200.
4. Efron B., Hastie T., Johnstone I., Tibshirani R. Least angle regression. Ann Stat 2004, 32:407-451.
5. Fan J., Lv J. Sure independence screening for ultrahigh dimensional feature space. J R Stat Soc Ser B 2008, 70:849-911.
6. Fleming T.R., Harrington D.P. Counting processes and survival analysis 1991, Wiley, New York.
7. Friedman J., Hastie T., Hofling H., Tibshirani R. Pathwise coordinate optimization. Ann Appl Stat 2007, 1:302-332.
8. Griffin J.E., Brown P. Bayesian hyper-Lassos with non-convex penalization. Aust N Z J Stat 2011, 53:423-442.
9. Kalbfleisch J.D. Nonparametric Bayesian analysis of survival time data. J R Stat Soc Ser B 1978, 40:214-221.
10. Kim E., Herbst R., Wistuba I., Lee J., Blumenschein G., Tsao A., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011, 1:44-53.
11. Kyung M., Gill J., Ghosh M., Casella G. Penalized regression, standard errors, and Bayesian Lassos. Bayesian Anal 2010, 5:369-412.
12. Meinshausen N. Lasso with relaxation. Comput Stat Data Anal 2007, 52:374-393.
13. Park T., Casella G. The Bayesian Lasso. J Am Stat Assoc 2008, 103:681-686.
14. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B 1996, 58:267-288.
15. Yuan M., Lin Y. Model selection and estimation in regression with grouped variables. J R Stat Soc Ser B 2006, 68:49-67.
16. Zhou X., Liu S., Kim E., Herbst R.S., Lee J. Bayesian adaptive design for targeted therapy development in lung cancer - a step toward personalized medicine. Clin Trials 2008, 5:181-193.
17. Zou H. The adaptive Lasso and its oracle properties. J Am Stat Assoc 2006, 101:1418-1429.